Drug induced sleep endoscopy for the treatment of patients with obstructive sleep apnea -An assessment of coding data

In recent years, drug induced sleep endoscopy (DISE) achieved increasing attention as a diagnostic tool in obstructive sleep apnea (OSA). Especially in hypoglossus nerve stimulation (HNS) in PAP failure, most implants require a DISE for indication. Up to now, general data regarding frequency for DISE and patient characteristics were not available. A specific operational and procedural code 1-611.01 for DISE was introduced in January 2021.

Using the database of the InEK institute, DISEs were identified which have been coded for hospital affiliated and in-patient procedures between January and May 2021. Information regarding concomitant diagnosis and hospital characteristics have been extracted from accounting data.

Between January and May 2021, 1,054 DISEs have been done and coded. The majority of the patients were male (75.3%) and showed a low rate of concomitant diagnosis (PCCL 0 = 82%). Two peaks could be detected for middle aged (40 to 49 years) and geriatric cases (65 to 74 years). Only 1.9% patients were minors. The main leading diagnosis was G47.31 (OSA) and J34.2 (nasal septal deviation). The most frequent concomitant procedures were nasal septum and lower turbinate interventions.

Considering the high prevalence of OSA in Germany, there is a low usage of coded DISEs. DISEs represent only 4.4% of the entire in-patient procedures coded with OSA. It was not possible to assess trends as the specific OPS code was introduced in January 2021. There is a striking high number of nasal intervention coded together with DISE. The frequency of now available data for DISEs allows an estimation of the ratio between documented DISE and HNS implantations in Germany.

Conflict of Interest Der Erstautor weist auf folgenden Interessenkonflikt hin Armin Steffen ist Berater der Fa. Inspire Medical.

Publikationsverlauf

Artikel online veröffentlicht:
24. Mai 2022